Your browser is no longer supported. Please, upgrade your browser.
Settings
XPH SPDR S&P Pharmaceuticals ETF daily Stock Chart
XPH [NYSE]
SPDR S&P Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-4.33%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-0.76%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-12.26%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio4.60 Perf Half Y-13.32%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-26.51%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range36.58 - 55.69 Perf YTD-23.98%
Dividend0.21 P/FCF- EPS past 5Y- ROI- 52W High-30.11% Beta-
Dividend %0.54% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low6.40% ATR0.98
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)36.67 Volatility1.92% 2.60%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.18 Prev Close38.62
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume212.41K Price38.92
Recom- SMA20-2.93% SMA50-7.32% SMA200-9.26% Volume248,905 Change0.78%
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
10:49AM  5 Secret Santa ETFs & Stocks for Your Portfolio
Dec-01-16 08:51AM  Five ways to evaluate an Obamacare replacement plan at MarketWatch
08:50AM  What to expect from HHS Secretary nominee and Obamacare opponent Tom Price at MarketWatch
Nov-30-16 06:21PM  A Closer Look at Mercks Valuation Compared to Peers
Nov-27-16 04:54PM  Where Else Have We Seen Mallinckrodts Acquire to Invest Strategy?
Nov-23-16 10:04AM  What You Need to Know about Eli Lillys Cardiovascular Franchise
Nov-22-16 11:04AM  What Do the Analysts Recommend for Bristol-Myers Squibbs Stock?
Nov-17-16 12:18PM  Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
Nov-16-16 08:15AM  Biotech takes Trump presidency as a green light and end to drug price worries at MarketWatch
Nov-14-16 10:57AM  5 Reasons to Buy 5 Low P/E Biotech ETFs
07:52AM  Corbus Pharmaceuticals stock more than doubles after positive drug trial results at MarketWatch
Nov-04-16 01:15PM  Healthcare: "A Better Buy Than A Sell" at Barrons.com
Oct-31-16 05:39PM  Can Key Level Stop The Bleeding In Health Care Stocks?
10:05AM  Understanding the Growth Contributors in Pfizers 3Q16 Estimates
10:04AM  Januvia and Janumet: Mercks Blockbuster Diabetes Products
Oct-20-16 05:48PM  Another Health Care Chart Looks Sick
08:04AM  Eli Lilly and Co.s 3Q16 Estimates: Cardiovascular Franchise
Oct-12-16 10:04AM  BMYs Drug Treatments That Go beyond Immuno-Oncology
Oct-10-16 11:04AM  Keytruda Leads over Opdivo in Head and Neck Cancer Treatment
Oct-04-16 10:04AM  A Look at Gardasil and Merck & Co.s Vaccines Business
Oct-03-16 08:05AM  Medicare Negotiations Would Lead to Huge Cost Savings
Sep-30-16 03:04PM  Analyzing Donald Trumps Free-Market Healthcare
11:15AM  Generic Drugs Are Crucial in Cost Savings and Accessibility
Sep-27-16 02:20PM  Getting Into The Drug Business: From NDAs To PDUFA Dates
Sep-26-16 11:05AM  How Mylans Profitability Has Changed
Sep-23-16 03:20PM  Are Mylans EpiPen Challenges Souring Analysts Views on Stock?
02:23PM  Pharma ETF Looks Healthy in a Sick Market After Endo Names New CEO
Sep-21-16 11:05AM  How Analysts See Horizon Compared to Its Peers
Sep-20-16 12:04PM  News of Acquisition Caused Horizon Pharma Stock to Rise
Sep-19-16 06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
Sep-12-16 02:47PM  M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound
09:30AM  The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical
Sep-09-16 03:39PM  Will a Clinton Presidency Spell Doom for Pharma ETFs?
Sep-06-16 11:22AM  Top Sector ETFs of Summer
Sep-05-16 11:04AM  Animal Health: Just as Important to Eli Lilly as Human Health
Aug-31-16 10:05AM  Why Pfizer Is Trading at a Discount on an Earnings Basis
Aug-30-16 10:04AM  Akorn in 2016: What Are Its Key Risk Factors?
Aug-24-16 11:04AM  How Did Bristol-Myers Squibb Fare in 2Q16?
Aug-22-16 09:06AM  How Did Bristol-Myers Squibbs Oncology Segment Perform in 2Q16?
Aug-19-16 11:04AM  Horizons Orphan Drug Business Faces These Opportunities
Aug-15-16 09:06AM  What Are Mercks Key Diabetes Products?
Aug-07-16 01:20PM  Obamacare Still Sickly, After All These Years
Aug-04-16 09:04AM  Eli Lillys Cardiovascular Franchise Keeps Posting Upbeat Revenues
Aug-03-16 12:22PM  Pharma ETFs Soaring on Solid Q2 Earnings
Jul-26-16 09:04AM  What Key Developments Did JNJ Announce in 2Q16?
Jul-25-16 02:24PM  Expectations for Bristol-Myers Squibbs 2Q16 Earnings
Jul-22-16 01:07PM  Inside Lillys 2Q16 Estimates for Its Cardiovascular Franchise
Jul-21-16 11:08AM  Best Sector ETFs for Q3
Jul-15-16 09:06AM  Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Jul-12-16 11:06AM  Check out Horizons Huge Upside Potential
Jul-07-16 07:06AM  Whats Really Driving Horizons Valuation?
May-20-16 10:05AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
09:30AM  Pharmaceuticals & Emerging Market: Two ETFs Trading with Outsized Volume
May-12-16 10:09AM  Januvia and Janumet: Mercks Blockbuster Diabetes Drugs
May-11-16 03:47PM  Mercks Valuation Cheat Sheet for Fiscal 1Q16
May-07-16 10:01AM  Mudslinging Over Valeant Pharmaceuticals
May-05-16 08:05PM  How Eli Lillys Cardiovascular Franchise Performed in 1Q16
May-04-16 02:50PM  Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus
09:00AM  Finding Pharmaceuticals ETFs With Rebound Potential
Apr-26-16 07:08PM  What Do Analysts Recommend for Jazz Pharmaceuticals?
Apr-20-16 06:06PM  Analyzing Akorns Strategy to Withstand Generic Industry Challenges
Apr-11-16 01:04AM  Is Mallinckrodt Spending Enough on R&D?
Apr-06-16 12:05PM  Your Horizon Breakdown: Performance across Segments
11:36AM  3 ETFs to Watch (XLF, IEV) at Investopedia
Mar-28-16 03:39PM  How Horizon Became a Growth Stock
Mar-24-16 01:26PM  Mylan Expected to Further Strengthen EpiPen Franchise in 2016
Mar-23-16 02:09PM  Where Else Have We Seen Mallinckrodts Acquire to Invest Strategy?
Mar-21-16 09:01AM  Better Buy: Intuitive Surgical, Inc. vs. Medtronic PLC at Motley Fool
Mar-18-16 08:07AM  Better Buy: AbbVie Inc. vs. Eli Lilly at Motley Fool
Mar-17-16 09:21AM  The 5-Minute Guide to Horizon Pharma PLC Stock at Motley Fool
Mar-12-16 08:25PM  Saturday links: poised for growth
Mar-09-16 06:37AM  5 Best Performing Bull Run Equity ETFs
Jan-28-16 12:04PM  Insight into Tevas Over-the-Counter and Distribution Businesses
Jan-04-16 01:50PM  What Does 2016 Hold in Store for Pharma ETFs
Dec-14-15 01:20PM  FEZ and EWJ Fall as Crude Oil Prices Plunge Further
Dec-09-15 05:54PM  DuPont-Dow Megadeal Talk Stirs Materials ETFs at Investor's Business Daily
08:06AM  Kite Pharma Leads IBBs Mid-Caps on Its Zuma-1 Phase 1 Results
Dec-08-15 06:56PM  Oil ETFs Dig A Hole But Could Syria Change That? at Investor's Business Daily
01:06PM  Consumer Staples Didnt Fall into Equity Markets Downtrend
01:03PM  SPY Ended Negative as Oil Sank to New Lows
12:07PM  Alexion Tops IBBs Large-Caps on Release of New Research Data
11:55AM  U.S. benchmarks rattle the cage on important support at MarketWatch
Dec-07-15 06:13PM  Jet ETF Climbs, Dow In Red For 2015 As Oil Weighs at Investor's Business Daily
05:34PM  Financial Sector Catches a Rate Hike Tailwind on December 4
05:34PM  Gung-Ho US Employment Scene Catapults SPY on December 4
03:45PM  How Are IBBs American Depositary Receipts Performing?
11:52AM  FEZ Rises by 1.2% on Strong Employment Data
07:05AM  IHIs Small Caps Outperformed the Market
07:05AM  Abiomed Rose 1% on High Trading Volume
Dec-05-15 07:40AM  These 3 ETFs Jumped in November at Motley Fool
12:01AM  [$$] Funds' Warmth Faces Cold Shoulders at Barrons.com
Dec-04-15 06:23PM  Gold Mining ETFs Spike As Metal Shines at Investor's Business Daily
03:07PM  Mallinckrodt Rose after Sale of Contrast Media & Delivery System
02:06PM  Rate Hike Hints Boost November Fund Flows of $731 Million in XLF
01:01PM  How Did Cooper Companies and Its Peers Perform?
01:00PM  Cooper Companies Income Rose in Fiscal 4Q15
12:22PM  Sell-Off in All the Component Sectors of the SPY ETF
12:22PM  Draghis Dovish Move Was Less than Expected, Affecting US Stocks
12:06PM  Investors Have Pulled $54 Million from KCE in 2015
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.